Emergent BioSolutions Inc.
EBS· NYSE
EBSEmergent BioSolutions Inc.
Filed Aug 6, 2026 · 10-Q · 37 days after period end · 0001367644-26-000082
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $234.30M | $140.90M | $254.70M | $337.90M |
| Net Income | -$180.20M | -$12.00M | -$283.10M | -$261.40M |
| EPS Diluted | -$3.49 | -$0.22 | -$5.38 | -$5.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end
